TY - JOUR
T1 - Lipid-lowering pharmacotherapy and socioeconomic status
T2 - Atherosclerosis risk in communities (ARIC) surveillance study
AU - Kitzmiller, Joseph P.
AU - Foraker, Randi E.
AU - Rose, Kathy M.
N1 - Funding Information:
The authors thank the staff of the ARIC study for their important contributions. This research was supported by NHLBI grant 1R01HL080287 and by NIGMS grant K23GM100372. It was also funded in part by National Institutes of Health, NHLBI, and National Research Service Award training grant 5-T32-HL007055-30. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022.
PY - 2013
Y1 - 2013
N2 - Background: Lipid-reduction pharmacotherapy is often employed to reduce morbidity and mortality risk for patients with dyslipidemia or established cardiovascular disease. Associations between socioeconomic factors and the prescribing and use of lipid-lowering agents have been reported in several developed countries. Methods. We evaluated the association of census tract-level neighborhood household income (nINC) and lipid-lowering medications received during hospitalization or at discharge among 3,546 (5,335 weighted) myocardial infarction (MI) events in the United States (US) Atherosclerosis Risk In Communities (ARIC) surveillance study (1999-2002). Models included neighborhood household income, race, gender, age, study community, year of MI, hospital type (teaching vs. nonteaching), current or past history of hypertension, diabetes or heart failure, and presence of cardiac pain. Results: About fifty-nine percent of patients received lipid-lowering pharmacotherapy during hospitalization or at discharge. Low nINC was associated with a lower likelihood (prevalence ratio 0.89, 95% confidence interval: 0.79, 1.01) of receiving lipid-lowering pharmacotherapy compared to high neighborhood household income, and no significant change in this association resulted when adjusted for the above-mentioned covariates. Conclusion: Patient's socioeconomic status appeared to influence whether they were prescribed a lipid-lowering pharmacotherapy after hospitalization for myocardial infarction in the US ARIC surveillance study (1999-2002).
AB - Background: Lipid-reduction pharmacotherapy is often employed to reduce morbidity and mortality risk for patients with dyslipidemia or established cardiovascular disease. Associations between socioeconomic factors and the prescribing and use of lipid-lowering agents have been reported in several developed countries. Methods. We evaluated the association of census tract-level neighborhood household income (nINC) and lipid-lowering medications received during hospitalization or at discharge among 3,546 (5,335 weighted) myocardial infarction (MI) events in the United States (US) Atherosclerosis Risk In Communities (ARIC) surveillance study (1999-2002). Models included neighborhood household income, race, gender, age, study community, year of MI, hospital type (teaching vs. nonteaching), current or past history of hypertension, diabetes or heart failure, and presence of cardiac pain. Results: About fifty-nine percent of patients received lipid-lowering pharmacotherapy during hospitalization or at discharge. Low nINC was associated with a lower likelihood (prevalence ratio 0.89, 95% confidence interval: 0.79, 1.01) of receiving lipid-lowering pharmacotherapy compared to high neighborhood household income, and no significant change in this association resulted when adjusted for the above-mentioned covariates. Conclusion: Patient's socioeconomic status appeared to influence whether they were prescribed a lipid-lowering pharmacotherapy after hospitalization for myocardial infarction in the US ARIC surveillance study (1999-2002).
KW - Cardiovascular disease
KW - Lipid-lowering pharmacotherapy
KW - Lipids
KW - Socioeconomics
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=84877869480&partnerID=8YFLogxK
U2 - 10.1186/1471-2458-13-488
DO - 10.1186/1471-2458-13-488
M3 - Article
C2 - 23688340
AN - SCOPUS:84877869480
SN - 1471-2458
VL - 13
JO - BMC Public Health
JF - BMC Public Health
IS - 1
M1 - 488
ER -